Several brokerages have updated their recommendations and price targets on shares of enGene (NASDAQ: ENGN) in the last few weeks:
- 10/16/2026 – enGene had its “buy” rating reaffirmed by HC Wainwright.
- 10/16/2026 – enGene was downgraded by Citigroup from “market perform” to “hold”.
- 10/15/2026 – enGene was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 10/13/2026 – enGene was upgraded by Jefferies Financial Group to “strong-buy”.
- 9/9/2026 – enGene had its “market perform” rating reaffirmed by Citigroup.
- 9/9/2026 – enGene had its “market perform” rating reaffirmed by Citizens Jmp.
- 9/8/2026 – enGene had its “buy” rating reaffirmed by HC Wainwright. They now have a $4.00 price target on the stock.
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Featured Stories
- Five stocks we like better than enGene
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
Receive News & Ratings for enGene Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
